Tofacitinib Citrate Patent Expiration
Tofacitinib Citrate is Used for treating moderate to severe ulcerative colitis and rheumatoid arthritis. It was first introduced by Pf Prism Cv
Tofacitinib Citrate Patents
Given below is the list of patents protecting Tofacitinib Citrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xeljanz Xr |
US10639309 (Pediatric) | Tofacitinib oral sustained release dosage forms | Sep 14, 2034 | Pfizer |
| Xeljanz Xr |
US11253523 (Pediatric) | Tofacitinib oral sustained release dosage forms | Sep 14, 2034 | Pfizer |
| Xeljanz Xr |
US9937181 (Pediatric) | Tofacitinib oral sustained release dosage forms | Sep 14, 2034 | Pfizer |
| Xeljanz Xr | US10639309 | Tofacitinib oral sustained release dosage forms | Mar 14, 2034 | Pfizer |
| Xeljanz Xr | US11253523 | Tofacitinib oral sustained release dosage forms | Mar 14, 2034 | Pfizer |
| Xeljanz Xr | US9937181 | Tofacitinib oral sustained release dosage forms | Mar 14, 2034 | Pfizer |
| Xeljanz |
USRE41783 (Pediatric) | Pyrrolo[2,3-D]pyrimidine compounds |
Jun 08, 2026
(Expired) | Pfizer |
| Xeljanz |
USRE41783 (Pediatric) | Pyrrolo[2,3-D]pyrimidine compounds |
Jun 08, 2026
(Expired) | Pf Prism Cv |
| Xeljanz Xr |
USRE41783 (Pediatric) | Pyrrolo[2,3-D]pyrimidine compounds |
Jun 08, 2026
(Expired) | Pfizer |
| Xeljanz | USRE41783 | Pyrrolo[2,3-D]pyrimidine compounds |
Dec 08, 2025
(Expired) | Pfizer |
| Xeljanz | USRE41783 | Pyrrolo[2,3-D]pyrimidine compounds |
Dec 08, 2025
(Expired) | Pf Prism Cv |
| Xeljanz Xr | USRE41783 | Pyrrolo[2,3-D]pyrimidine compounds |
Dec 08, 2025
(Expired) | Pfizer |
| Xeljanz | US6965027 | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar 25, 2023
(Expired) | Pf Prism Cv |
| Xeljanz | US6965027 | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar 25, 2023
(Expired) | Pf Prism Cv |
| Xeljanz Xr | US6956027 | N-terminally chemically modified protein compositions and methods |
Mar 25, 2023
(Expired) | Pfizer |
| Xeljanz Xr | US6965027 | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar 25, 2023
(Expired) | Pfizer |
| Xeljanz | US7301023 | Chiral salt resolution |
May 23, 2022
(Expired) | Pf Prism Cv |
| Xeljanz | US6956041 | Pyrrolo[2,3-d]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pf Prism Cv |
| Xeljanz | US7091208 | Pyrrolo[2,3-D]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pf Prism Cv |
| Xeljanz | US7265221 | Pyrrolo[2,3-d]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pf Prism Cv |
| Xeljanz | US7265221 | Pyrrolo[2,3-d]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pf Prism Cv |
| Xeljanz | US7301023 | Chiral salt resolution |
Dec 08, 2020
(Expired) | Pf Prism Cv |
| Xeljanz | US7842699 | Pyrrolo[2,3-D]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pf Prism Cv |
| Xeljanz Xr | US6956041 | Pyrrolo[2,3-d]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pfizer |
| Xeljanz Xr | US7091208 | Pyrrolo[2,3-D]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pfizer |
| Xeljanz Xr | US7265221 | Pyrrolo[2,3-d]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pfizer |
| Xeljanz Xr | US7301023 | Chiral salt resolution |
Dec 08, 2020
(Expired) | Pfizer |
| Xeljanz Xr | US7842699 | Pyrrolo[2,3-D]pyrimidine compounds |
Dec 08, 2020
(Expired) | Pfizer |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Tofacitinib Citrate's patents.
Latest Legal Activities on Tofacitinib Citrate's Patents
Given below is the list recent legal activities going on the following patents of Tofacitinib Citrate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Sep, 2025 | US9937181 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Jul, 2025 | US11253523 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Oct, 2023 | US10639309 |
| Expire Patent Critical
| 02 Jan, 2023 | US7842699 |
| Maintenance Fee Reminder Mailed Critical
| 18 Jul, 2022 | US7842699 |
| Recordation of Patent Grant Mailed Critical
| 22 Feb, 2022 | US11253523 |
| Patent Issue Date Used in PTA Calculation Critical
| 22 Feb, 2022 | US11253523 |
| Email Notification Critical
| 03 Feb, 2022 | US11253523 |
| Issue Notification Mailed Critical
| 02 Feb, 2022 | US11253523 |
| Mailing Corrected Notice of Allowability | 27 Jan, 2022 | US11253523 |
Tofacitinib Citrate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Tofacitinib Citrate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease | National Institute of Dental and Craniofacial Research (NIDCR) | NA |
RECRUITING
(Sep 15, 2026)
| PHASE2 |
| A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |